drugset / Trial / NCT01784536

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

NCT01784536

Phase 1 Completed 16 enrolled Melinta Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Oritavancin Other / unclassified Intravenous

Indications

No indication recorded.